Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Lymphocytic choriomeningitis virus (LCMV) exhibits natural tropism for dendritic cells and represents the prototypic infection that elicits protective CD8(+) T cell (cytotoxic T lymphocyte (CTL)) immunity. Here we have harnessed the immunobiology of this arenavirus for vaccine delivery. By using producer cells constitutively synthesizing the viral glycoprotein (GP), it was possible to replace the gene encoding LCMV GP with vaccine antigens to create replication-defective vaccine vectors. These rLCMV vaccines elicited CTL responses that were equivalent to or greater than those elicited by recombinant adenovirus 5 or recombinant vaccinia virus in their magnitude and cytokine profiles, and they exhibited more effective protection in several models. In contrast to recombinant adenovirus 5, rLCMV failed to elicit vector-specific antibody immunity, which facilitated re-administration of the same vector for booster vaccination. In addition, rLCMV elicited T helper type 1 CD4+ T cell responses and protective neutralizing antibodies to vaccine antigens. These features, together with low seroprevalence in humans, suggest that rLCMV may show utility as a vaccine platform against infectious diseases and cancer.

Original publication

DOI

10.1038/nm.2104

Type

Journal article

Journal

Nature medicine

Publication Date

03/2010

Volume

16

Pages

339 - 345

Addresses

Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. lukas.flatz@gmail.com

Keywords

Dendritic Cells, CD8-Positive T-Lymphocytes, Animals, Mice, Inbred C57BL, Mice, Transgenic, Mice, Lymphocytic choriomeningitis virus, Arenaviridae Infections, Vaccines, Synthetic, Viral Vaccines, Immunization, Secondary, Lymphocyte Activation, Antibody Formation, Dose-Response Relationship, Immunologic, Immunity, Cellular, Genetic Vectors